Research library / Multivitamins
BB Good human data, but mixed outcomes or surrogate markers. How we grade →RCT (double-blind) · 14,641 male physicians aged 50+, median 11.2 years
Multivitamins in the Prevention of Cardiovascular Disease in Men: The Physicians' Health Study II Randomized Controlled Trial
H Sesso, W Christen, V Bubes, J Smith, J MacFadyen, M Schvartz et al. JAMA. 2012.
- In plain language
- PHS II: a daily multivitamin did not reduce major cardiovascular events (HR 1.01), heart attack or stroke.
- Limits
- Male physicians only; one product (Centrum Silver); BASF investigator-initiated grant and donated study pills.
- Which of our grades it feeds
- CC Small or few human trials. Promising, not proven. How we grade →Science summary: Daily multivitamins: what the large randomized trials show
- CC Small or few human trials. Promising, not proven. How we grade →Ratings card: Daily multivitamin: Filling common nutrient gaps
- Source
- doi.org/10.1001/jama.2012.14805 · PubMed 23117775
Summary written by Everstack from the published abstract. Verified against Crossref on 2026-10-15. The authors do not endorse Everstack. We sell some of what we grade.